The Union Budget 2026–27 has delivered a major shot in the arm to India's pharmaceutical and biopharmaceutical sector with the launch of the Biopharma SHAKTI initiative. This ambitious program comes with a substantial ₹10,000 crore allocation spread over the next five years, aimed at building a robust end-to-end ecosystem for biologics, biosimilars, advanced manufacturing, clinical research, and regulatory enhancements. What is Biopharma SHAKTI? Biopharma SHAKTI (Strategy for Healthcare Advancement through Knowledge, Technology and Innovation) is designed to position India as a global biopharma manufacturing hub . It focuses on shifting the industry from traditional generics toward high-value, innovation-driven products like biologics and biosimilars — critical for treating non-communicable diseases such as cancer, diabetes, and autoimmune disorders. Key components include: Strengthening domestic production capabilities to reduce import dependence on complex biologic drugs. ...
- Get link
- X
- Other Apps